OnKure Therapeutics, Inc. Net Assets
OnKure Therapeutics, Inc. net assets. Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has net assets worth $172.11 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($179.35 Million) and total liabilities ($7.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore OnKure Therapeutics, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $172.11 Million |
| % of Total Assets | 95.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.83% |
| 10-Year Change | N/A |
| Growth Volatility | 45.54 |
Net Assets of OnKure Therapeutics, Inc. (2020–2025)
Net assets of OnKure Therapeutics, Inc. from 2020 to 2025. This chart illustrates how OnKure Therapeutics, Inc.'s net assets have evolved over time, based on quarterly financial data. See OKUR equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for OnKure Therapeutics, Inc. (2020–2025)
The table below shows the annual net assets of OnKure Therapeutics, Inc. from 2020 to 2025. For live market cap and overall valuation, see OKUR stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $56.18 Million | -45.89% |
| 2024-12-31 | $103.83 Million | +201.95% |
| 2023-12-31 | $-101.84 Million | -87.15% |
| 2022-12-31 | $-54.42 Million | -136.97% |
| 2021-12-31 | $147.21 Million | +449.55% |
| 2020-12-31 | $-42.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OnKure Therapeutics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16928300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
OnKure Therapeutics, Inc. Net Assets Breakdown (December 2025)
OnKure Therapeutics, Inc. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $270.42 Million | 481.32% |
| Total Equity | $56.18 Million | 100.00% |
OnKure Therapeutics, Inc. Competitors by Market Cap
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Carnaby Resources Ltd
AU:CNB
|
$104.93 Million |
|
Social Commerce Partners Corporation Class A Ordinary Shares
NASDAQ:SCPQ
|
$104.95 Million |
|
Ctek AB
ST:CTEK
|
$104.98 Million |
|
Honghua Group Limited
F:4HB
|
$104.98 Million |
|
Min Aik Technology Co Ltd
TW:3060
|
$104.88 Million |
|
Sejong Industrial
KO:033530
|
$104.86 Million |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
$104.85 Million |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
$104.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OnKure Therapeutics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 103,828,000 to 56,184,000, a change of -47,644,000 (-45.9%).
- Net loss of 59,517,000 reduced equity.
- Other factors increased equity by 11,873,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.52 Million | -105.93% |
| Other Changes | $11.87 Million | +21.13% |
| Total Change | $- | -45.89% |
Book Value vs Market Value Analysis
This analysis compares OnKure Therapeutics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.62x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-16.75 | $2.59 | x |
| 2021-12-31 | $81.14 | $2.59 | x |
| 2022-12-31 | $-4.08 | $2.59 | x |
| 2023-12-31 | $-7.63 | $2.59 | x |
| 2024-12-31 | $7.78 | $2.59 | x |
| 2025-12-31 | $4.16 | $2.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OnKure Therapeutics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -105.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-105.93%) is below the historical average (-30.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.25 Million |
| 2021 | -27.02% | 0.00% | 0.00x | 1.05x | $-54.49 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.07 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.13 Million |
| 2024 | -50.73% | 0.00% | 0.00x | 1.11x | $-63.06 Million |
| 2025 | -105.93% | 0.00% | 0.00x | 1.11x | $-65.14 Million |
Industry Comparison
This section compares OnKure Therapeutics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | $172.11 Million | 0.00% | 0.04x | $104.89 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more